Latest Breaking News On - Chronic urticaria - Page 1 : vimarsana.com

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 - Jasper Therapeutics (NASDAQ:JSPR)

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting

United statesLauren walkerAlex grayJoyce allaireEdwin tuckerEuropean academy of allergyJasper therapeutics incSingle subcutaneous sc administration to healthyEuropean academyClinical immunologyKit mouseWendy pangSenior vice presidentTranslational medicineChief medical officerDose escalation study

Jasper Therapeutics to Present Data on Briquilimab in Mast

Jasper Therapeutics to Present Data on Briquilimab in Mast
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesAlex grayJoyce allaireEdwin tuckerLauren walkerEuropean academy of allergySingle subcutaneous sc administration to healthyJasper therapeutics incEuropean academyClinical immunologyKit mouseWendy pangSenior vice presidentTranslational medicineChief medical officerDose escalation study

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesLauren walkerEdwin tuckerAlex grayJoyce allaireSingle subcutaneous sc administration to healthyEuropean academy of allergyJasper therapeutics incPresent dataMast cell driven diseasesEuropean academyClinical immunologyKit mouseWendy pangSenior vice presidentTranslational medicine

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with.

District of columbiaUnited statesUnited kingdomPercy carterBecker hewesExchange commissionEuropean commissionDrug administrationConvention centerPrnewswire blueprint medicines corporation nasdaqAmerican academy of allergyMedicines corporationAnnual meetingChief medical officerBlueprint medicinesDurable symptom impact

Blueprint Medicines Highlights AYVAKIT® (Avapritinib) Long-Term Efficacy And Safety Data And Advances In Mast Cell Disease Research At 2024 AAAAI Annu

Blueprint Medicines Highlights AYVAKIT® (Avapritinib) Long-Term Efficacy And Safety Data And Advances In Mast Cell Disease Research At 2024 AAAAI Annu
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesUnited kingdomPercy carterBecker hewesBlueprint medicines corporationExchange commissionEuropean commissionAmerican academy of allergyPrnewswire blueprint medicines corporation nasdaqDrug administrationConvention centerMedicines corporationAnnual meetingChief medical officerBlueprint medicines